MBX Biosciences (NASDAQ:MBX) Issues Earnings Results

MBX Biosciences (NASDAQ:MBX) issued its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, FiscalAI reports.

MBX Biosciences Stock Performance

NASDAQ:MBX opened at $28.56 on Thursday. The firm has a market capitalization of $1.28 billion, a PE ratio of -12.01 and a beta of 1.06. The stock’s fifty day moving average is $35.69 and its 200 day moving average is $26.42. MBX Biosciences has a fifty-two week low of $4.81 and a fifty-two week high of $44.89.

Analysts Set New Price Targets

Several brokerages recently weighed in on MBX. Weiss Ratings restated a “sell (d-)” rating on shares of MBX Biosciences in a research report on Thursday, January 22nd. Guggenheim increased their price objective on shares of MBX Biosciences from $77.00 to $88.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Barclays initiated coverage on shares of MBX Biosciences in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $66.00 price objective for the company. Truist Financial set a $50.00 target price on shares of MBX Biosciences in a report on Monday. Finally, Stifel Nicolaus increased their price target on shares of MBX Biosciences from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, December 19th. Ten investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $51.56.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. raised its stake in shares of MBX Biosciences by 4,131.4% in the third quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock valued at $26,000 after acquiring an additional 1,446 shares during the period. FNY Investment Advisers LLC bought a new position in MBX Biosciences during the 3rd quarter valued at about $27,000. GF Fund Management CO. LTD. bought a new position in MBX Biosciences during the 4th quarter valued at about $28,000. Royal Bank of Canada raised its position in MBX Biosciences by 59.6% in the 4th quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock worth $49,000 after purchasing an additional 572 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in MBX Biosciences by 117.9% in the third quarter. BNP Paribas Financial Markets now owns 2,896 shares of the company’s stock worth $51,000 after purchasing an additional 1,567 shares during the last quarter.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.